About Cogent Biosciences
Cogent Biosciences is a publicly listed company based in Cambridge (United States) founded in 2014 by Charles Wilson. Precision therapies for genetically defined diseases are developed. Cogent Biosciences has raised $77 million across 6 funding rounds from investors including Pfizer, New Leaf Venture Partners and TD Securities. The company has 205 employees. Cogent Biosciences has completed 1 acquisition, including kiq.com. Its chief executive, as recorded, is Charles Wilson. Its website cogentbio.com draws about 13 thousand monthly visits. Cogent Biosciences offers products and services including Bezuclastinib, ErbB2 Program, FGFR2 Program, PI3KΞ± Program, and KRAS Program. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its legal entity is Cogent Biosciences, Inc. Its competitors include BridgeBio, Moderna and C4 Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Cogent Biosciences was founded in 2014 and is headquartered in Cambridge, United States. Precision therapies are developed by the company for genetically driven diseases, including cancer, rare diseases, and autoimmune conditions. Operations focus on kinase inhibitors, with the lead product PLX9486 designed to target the KIT D816V mutation. This therapeutic is being advanced for gastrointestinal stromal tumors reliant on oncogenic KIT signaling.
- Headquarters Cambridge, United States
- Employees 205
- Founders Charles Wilson
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website cogentbio.com
- Social LinkedIn X
- Legal Name Cogent Biosciences, Inc.
Products & Services of Cogent Biosciences
Cogent Biosciences offers a comprehensive portfolio of products and services, including Bezuclastinib, ErbB2 Program, FGFR2 Program, PI3Kα Program, and KRAS Program.
Targets Systemic Mastocytosis and related cancers
Develops treatments for specific genetic mutations
Focuses on precision therapies for genetic diseases
Advances targeted treatments in oncology
Creates solutions for genetically driven cancers
Funding Insights of Cogent Biosciences
Cogent Biosciences has successfully raised a total of $77M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $77M
- Total Rounds 6
- First Round $12M
(Oct 2014)
- Investors Count 21
All 6 funding rounds of Cogent Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | Post-IPO | β | β | ||
| Jul 2020 | $104.4M | Post-IPO | β | β | β |
| Mar 2020 | $25M | Post-IPO | β | β | |
| Mar 2017 | $15M | Debt – Venture | β | β | β |
| Jun 2015 | $65M | Series B | β | F-Prime Capital, Jennison | β |
| Oct 2014 | $12M | Series A | β | F-Prime Capital, Atlas Venture | β |
21 investors in total: 21 institutional.
Investors in Cogent Biosciences
Cogent Biosciences has secured backing from 21 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, New Leaf Venture Partners and TD Securities.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is provided to healthcare startups by Commodore Capital. | commodorecapital.com | New York, United States | ||
| tcgcrossover.com | ||||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Private equity investments are directed toward North American opportunities. | lpcfunds.com | Chicago, United States | ||
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Sectoral Asset Management is focused on global healthcare investment. | 2000 | sectoral.com | Montreal, Canada | |
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Brace Pharma Capital is focused on investing in innovative therapies. | bracepharma.com | Atlanta, United States |
Investor details for Cogent Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cogent Biosciences
99 people are tracked at Cogent Biosciences (54 in leadership, 9 in board & advisors, 36 in team); the tracked headcount is 205.
| Name | Role | Group |
|---|---|---|
Charles Wilson | Founder & CEO | Leadership |
Maggie Ascolillo | Director Data Management | Leadership |
Emily Plummer | Director, Global Scientific Communications | Leadership |
Aaron Smith | Director - Medicinal Chemistry | Leadership |
Bryan Grace | Director Of IT | Leadership |
Aarthi I. | Senior Director, Senior Corporate Counsel | Leadership |
Eiu K. | Vice President Information Technology | Leadership |
Joseph Kietzmann | Senior Director, HR Business Partner | Leadership |
Rachael Easton | Senior Vice President, Clinical Development | Leadership |
Pharm D. Hina Jolin | Senior Director - Clinical Science | Leadership |
Julia Lawrence | Senior Medical Director | Leadership |
Megan Clark | Vice President, Controller | Leadership |
Andrew Robbins | CEO & President | Leadership |
John Robinson | Chief Scientific Officer | Leadership |
Jennifer Garon | Compliance Director | Leadership |
John Fischer | Senior Director | Leadership |
Lora Marden | Vice President, Patient Advocacy, Engagement & Innovation | Leadership |
Hilary D'Anna | Associate Director, Patient Advocacy, Engagement & Innovation | Leadership |
Francis Sullivan | VP, Enzymology & Structural Biology | Leadership |
Evan Kearns | Chief Legal Officer & Corporate Secretary | Leadership |
79 more people are available in the full profile.
Complete people profiles for Cogent Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Cogent Biosciences
Cogent Biosciences is a publicly listed company on the NASDAQ with ticker symbol COGT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Mar 2018
- Listed onNASDAQ: COGT
- Listed entityCogent Biosciences, Inc.
- Exchange sectorHealth technology
- ISINUS19240Q2012
- Share price$28.09 (-5.67% on the day) · 2026-10-13
- Market capitalisation$4.87B
- EPS (diluted, trailing year)$-2.44
- Volume (last session)2,995,450
Financials of Cogent Biosciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$328.9M | -$328.7M | |
| 2024 | -$255.9M | -$271.5M | |
| 2023 | -$192.4M | -$204.5M | |
| 2022 | -$140.2M | -$142.0M | |
| 2021 | -$72.3M | -$75.4M |
Detailed financial statements for Cogent Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cogent Biosciences
Cogent Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include kiq.com.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Limited public information is available on kiq.com's core activities. | kiq.com | 1998 | Jul 2020 | β’β’β’β’ |
Complete acquisition details for Cogent Biosciences
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Cogent Biosciences
5 dated milestones of Cogent Biosciences across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Cogent Biosciences is founded.
- Funding First funding round of $12.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires kiq.com.
- Funding Latest funding round, Post-IPO,.
Competitors of Cogent Biosciences
Cogent Biosciences has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Moderna and C4 Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Cogent Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cogent Biosciences
The website of Cogent Biosciences (cogentbio.com) receives about 13.2K visits a month and ranks #1,909,084 among all websites worldwide, #2,608 in Biotechnology and Pharmaceuticals.
- Monthly visits13.2K
▲ 8.4% vs previous month
- Unique visitors5.4K
per month
- Global rank#1,909,084
among all websites
- Category rank#2,608
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit2.0
- Average visit1 min 34 sec
- DevicesDesktop 46% Β· Mobile 54%
Websites whose visitors overlap most with Cogent Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| agcbio.com | 100% | #910,858 | View details | ||
bioworld.com | bioworld.com | 89% | #311,180 | β | |
eaaci.org | eaaci.org | 77% | #544,320 | β | |
| rarediseaseadvisor.com | 53% | #485,606 | View details | ||
onclive.com | onclive.com | 53% | #306,443 | β | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 7 similar websites and full traffic analytics for Cogent Biosciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Cogent Biosciences (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cogent Biosciences
Complete news archive for Cogent Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cogent Biosciences
Cogent Biosciences was founded in 2014.
Cogent Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Charles Wilson is the CEO of Cogent Biosciences, as recorded in our data. They have also founded this company.
Cogent Biosciences is a funded company, having raised a total of $77M across 6 funding rounds to date. The company's 1st funding round was a Series A of $12M, raised on Oct 2014.
Cogent Biosciences has 205 employees.
Cogent Biosciences was founded in 2014 and is headquartered in Cambridge, United States. Precision therapies are developed by the company for genetically driven diseases, including cancer, rare diseases, and autoimmune conditions. Operations focus on kinase inhibitors, with the lead product PLX9486 designed to target the KIT D816V mutation. This therapeutic is being advanced for gastrointestinal stromal tumors reliant on oncogenic KIT signaling.
Cogent Biosciences's top competitors include Moderna, BridgeBio and C4 Therapeutics.
Cogent Biosciences offers Bezuclastinib, ErbB2 Program, FGFR2 Program, PI3KΞ± Program, and KRAS Program.
Yes, Cogent Biosciences is publicly traded on NASDAQ under the ticker symbol COGT.
Cogent Biosciences has made 1 acquisition, including kiq.com.
Cogent Biosciences has 21 investors. Key investors include Pfizer, New Leaf Venture Partners, TD Securities, Atlas Venture, and Perceptive Advisors.
Cogent Biosciences operates through Cogent Biosciences, Inc..